Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-12-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司2023年第三次临时股东大会法律意见书
Regulatory Filings
2023-12-26 Chinese
金宇生物技术股份有限公司2023年第三次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's third extraordinary general meeting of shareholders in 2023. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholder meeting rather than presenting financial data or management commentary. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it is not a report publication announcement or a regulatory filing. Therefore, the classification is DVA with high confidence.
2023-12-26 Chinese
金宇生物技术股份有限公司2023年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2023 Third Extraordinary General Meeting of Shareholders" of 金宇生物技术股份有限公司. It contains detailed agenda items, meeting procedures, and proposed amendments to company governance documents such as the Articles of Association, Board Meeting Rules, and Independent Director Work System. The content is focused on the meeting materials and agenda for a shareholders' meeting rather than the announcement of voting results or the minutes of the meeting. The document length is 4466 characters, which is relatively short but contains substantive meeting materials rather than just an announcement or a brief notice. The document is clearly a set of meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholder meetings. Although this is an extraordinary meeting, the category AGM-R is the closest and most appropriate classification for shareholder meeting materials. It is not a voting results announcement (DVA) because it does not contain voting outcomes, nor is it a proxy solicitation (PSI) or a regulatory filing (RNS). Therefore, the correct classification is AGM-R with high confidence.
2023-12-18 Chinese
金宇生物技术股份有限公司关于签订非洲猪瘟mRNA疫苗合作开发协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 金宇生物技术股份有限公司 regarding the signing of a cooperation development agreement for an African Swine Fever mRNA vaccine. It details the parties involved, the nature of the collaboration, the scope of the project, and risk disclosures. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a strategic collaboration agreement, not a financial report or regulatory filing about financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a proxy, voting result, or remuneration report. The document is a formal announcement of a business cooperation agreement, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-08 Chinese
金宇生物技术股份有限公司关于召开2023年第三次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a notice about convening the 2023 third extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information on shareholder voting rights, registration, and proxy authorization. There is no financial data, earnings, or report content. The document is an announcement of a shareholder meeting, not a report or results announcement. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and voting procedures rather than solicitation materials, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA) as it relates to shareholder voting and meeting details. Confidence is high due to clear meeting and voting focus and absence of financial or management report content.
2023-12-08 Chinese
金宇生物技术股份有限公司关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) for investors. It references the previously published 2023 third quarter report but does not contain the report itself or detailed financial data. The document provides information on the meeting time, location, participation method, and contact details. It is essentially an invitation and informational notice about the earnings call event rather than the earnings release or the full quarterly report. Given the content and length (1500 characters), this fits the category of an Investor Presentation (IP) or possibly a Call Transcript (CT) if it contained the transcript. However, since it is an announcement of the meeting and not the transcript or presentation slides, it is best classified as an Investor Presentation (IP) type document, as it focuses on the earnings explanation meeting for investors.
2023-12-06 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.